Novartis Reclaims Anthos, Reenters Factor XI Race
CardiacWire
FEBRUARY 12, 2025
Just a couple weeks after the full trial results of AZALEA TIMI 71 were released, Novartis agreed to acquire Anthos Therapeutics for $925M upfront and another $2.15B in milestone payments, signaling that the pharma titan may have renewed confidence in abelacimab and the Factor XI inhibition segment. Novartis spun out the testing and development of abelacimab and formed Anthos Therapeutics back in 2019.
Let's personalize your content